• If you are wondering whether Merit Medical Systems at around US$67.55 is starting to look appealing or still feels expensive, the recent share performance gives you a useful starting point.
• The stock has seen a 3.8% decline over the last 7 days, a 17.8% fall over the last 30 days, and is down 21.9% year to date and 35.5% over the past year, while the 5 year return stands at 13.4%.
• These moves have put more attention on how the market currently prices Merit Medical Systems and whether expectations have shifted too far in either direction. In this context, recent company and sector news has been interpreted by investors through the lens of changing risk and growth expectations, which can influence how quickly prices adjust.
• Merit Medical Systems currently has a valuation score of 2/6. The next step is to compare what different valuation methods say about the stock today and then look at a more complete way to frame value that will be covered at the end of this article.

Merit Medical Systems scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Merit Medical Systems Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s dollars to estimate what the entire business could be worth right now.

For Merit Medical Systems, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $238.8 million. Analyst inputs and subsequent extrapolations suggest free cash flow projections such as $226.3 million in 2026, $251.9 million in 2027 and $255.4 million in 2028, with further estimates extending out to 2035 based on Simply Wall St assumptions.

When all of these projected cash flows are discounted back using this DCF framework, the resulting estimated intrinsic value is about $81.76 per share. Compared with the recent share price of around $67.55, this implies the stock is about 17.4% undervalued according to this specific model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Merit Medical Systems is undervalued by 17.4%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Approach 2: Merit Medical Systems Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much investors are currently paying for each dollar of earnings, which helps you quickly compare pricing across similar businesses.

What counts as a reasonable P/E depends on what the market thinks about a company’s growth prospects and risk profile. Higher expected growth and lower perceived risk often go with a higher P/E, while slower expected growth or higher risk usually go with a lower P/E.

Merit Medical Systems currently trades on a P/E of 31.24x, compared with the Medical Equipment industry average of about 27.50x and a peer group average of 16.05x. Simply Wall St’s Fair Ratio for Merit Medical Systems is 24.94x, which is a proprietary estimate of what the P/E might look like after considering factors such as earnings growth, profit margins, industry, market cap and specific risks.

This Fair Ratio can be more informative than a simple industry or peer comparison because it adjusts for the company’s own characteristics rather than assuming all medical equipment stocks should share the same P/E.

Since the current P/E of 31.24x is above the Fair Ratio of 24.94x, the stock screens as overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Merit Medical Systems Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as your way of attaching a clear story about Merit Medical Systems to the numbers you care about. Narratives link your view on its products, reimbursement risks or international exposure to a financial forecast and a fair value on Simply Wall St’s Community page. You can then compare that fair value to the current price to help you decide if the stock looks attractive or stretched. Each Narrative automatically updates as new news or earnings arrive and allows very different views to sit side by side. For example, one investor might focus on WRAPSODY CIE, margin expansion and a fair value closer to the higher analyst target of US$122, while another might worry more about trade risks, reimbursement delays and premium product reliance, and use assumptions that support a fair value nearer the lower target of US$90.

Do you think there's more to the story for Merit Medical Systems? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.